trending Market Intelligence /marketintelligence/en/news-insights/trending/VDNg_wx-jVJHORYAY7H8lQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CTI BioPharma closes preferred stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CTI BioPharma closes preferred stock offering

Cell Therapeutics Inc. closed an underwritten public offering of 22,500 series N-3 preferred shares at $2,000 apiece for net proceeds of about $42.8 million.

The company will use the net proceeds to conduct a clinical trial, submit a new marketing authorization application for pacritinib to the European Medicines Agency, conduct additional research for the possible application of pacritinib in indications other than myelofibrosis, complete another clinical trial and for general corporate purposes.

Jefferies LLC acted as the sole book-running manager for the offering, with BTIG LLC as the lead manager.